Art Bioscience
Israel - RehovotBiotechnology
Focus: Art Bioscience is a publicly traded Israeli biotechnology company focused on DMD (Duchenne Muscular Dystrophy) gene therapy. The company operates at a preclinical/early-stage development phase with a specialized therapeutic focus.
Profile data last refreshed 16h ago · AI intelligence enriched 2d ago
Funding Stage
PUBLIC
Open Jobs
3
Should You Work at Art Bioscience?
AI assessmentArt Bioscience represents a speculative early-stage gene therapy play suitable for scientists seeking deep technical expertise in DMD but carries execution and financial transparency risks.
Why Work Here
- Focused therapeutic area (DMD gene therapy) allows deep specialization in a high-need rare disease with significant commercial opportunity
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Art Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.